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Abstract 
BACKGROUND: Dengue fever is the most serious consequence of mosquito-borne infection worldwide. The 
pathophysiology of DHF in human is complex, which involve endothelial cell activation and impaired endothelial 
barrier leading to plasma leakage triggering the activation of the haemostatic system. The increased vascular 
permeability may lead to hypovolemia, hypotension and shock, which is life-threatening. 
AIM: The objective of the study was to determine the effects of dengue haemorrhagic fever on the vascular 
endothelium. 
METHODS: Fifty patients (males 34, females 16), were recruited, Grade 1 (n = 41), Grade 2 (n = 6), Grade 3 (n = 
2) and Grade 4 (n = 1) DHF. Blood sampling was performed at the febrile, defervescence and convalescent 
phases for the determination of haemoglobin, haematocrit, platelets, prothrombin fragment F1 + 2, Von 
Willebrand Factor (VWF), vascular endothelial growth factor (VEGF) and D-dimer levels. Fifteen normal subjects 
were recruited to serve as normal controls. 
RESULTS: The patients aged between 4 and 54 years old. Grades 1 & 2 DHF showed no significant differences 
in the parameters studied. However, thrombocytopenia, elevated F1 + 2, VWF, VEGF and D-dimer levels were 
evident in febrile, defervescence and convalescent phases suggesting endothelial activation and plasma leakage. 
Pleural effusion was observed only in severe DHF. The three patients with Grades 3 and 4 DHF had similar study 
results. No mortality was recorded in the study. 
CONCLUSION: In dengue haemorrhagic fever, the vascular endothelium is activated, causing plasma leakage 
triggering the activation of the haemostatic system creating a hypercoagulable and enhanced fibrinolytic state 
evident by marked fibrinolysis. 
 
 
Introduction 
 
Dengue fever is the most serious 
consequence of mosquito-borne infection worldwide. 
There are more than 2.5 billion persons at risk of 
infection and occur mainly in the sub-tropical regions 
of Asia, Africa, and America [1] and the attacks have 
shifted mainly to adults [2]. The actual numbers of 
dengue cases are underreported or misclassified [3]. 
One study estimated that 3.9 billion people in 128 
countries are at risk of infection with dengue viruses 
[4]. In Indonesia, the overall incidence increased 
significantly from 0.05 / 100,000 in 1968 to 35-40 / 
100,000 in 2013 [5]. Clinical manifestations of DF 
include mild or marked febrile syndromes of abrupt 
onset with headache, pain behind the eyes muscle 
and bone pain, nausea, vomiting and rash. There is 
no specific treatment for dengue fever, but 
maintaining patients’ body fluid volume is critical. 
Dengue as defined by WHO [6] as dengue with and 
without warning signs of plasma leakage and defined 
into four grades (Grades 1 to 4). 
The pathophysiology of DHF in human is 
complex and the clinical symptoms due mainly to 
immune response, which also involve endothelial cell 
activation leading to plasma leakage and triggering 
the activation of the haemostatic system. The 
endothelium plays an important regulatory role in the 
circulation as a physical barrier and involved in the 
control of thrombosis and thrombolysis, vascular tone 
and growth of blood vessels [7]. It plays a critical role 
in a variety of human disorders. Endothelial injury is 
associated with elevated Von Willebrand Factor 
(VWF) and vascular endothelial growth factor (VEGF) 
a known potent regulator of vascular permeability and 
angiogenesis is released by platelets [8], [9]. The 
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platelets are the main transporter of VEGF [10]. 
Endothelial activation may be responsible for plasma 
leakage and shock [11]. D-dimer, the lysis product of 
cross-linked fibrin indicates hyperfibrinolysis in 
response to clotting activation and fibrin formation [12] 
It is also a marker for hypercoagulability and has been 
used to determine thrombosis in myeloproliferative 
disease [13], [14]. Thrombocytopenia is commonly 
observed in both mild and severe dengue syndrome 
and associated with clinical outcome [6], [15], [16], 
[17]. This may be due to bone marrow suppression, 
destruction and lengthening of the platelet life cycle 
[18], [19]. The level of platelet count correlates with 
severity of DHF, and high haematocrit with marked 
thrombocytopenia support the diagnosis of dengue 
shock syndrome (DSS) [2]. It has been considered as 
an important factor responsible for bleeding events in 
DHF [20]. Platelet activation is significantly increased 
in dengue-patients, especially with thrombocytopenia, 
which exhibited signs of apoptosis pathway activation 
[21]. Increased activation of coagulation (prothrombin 
fragment 1 + 2) was reported in a critical phase of 
severe dengue infection associated with plasma 
leakage and thrombocytopenia [2]. In the Brazilian 
study, it was reported that elevated D-dimer and 
thrombocytopenia with reduced thrombin generation 
and excessive fibrinolysis are associated with 
bleeding complications [23]. 
The objective of the study was to determine 
the effects of dengue haemorrhagic fever on the 
vascular endothelium. 
 
 
Material and Method 
 
The study received ethical approval from the 
Health Research Ethical Committee No 418 / TGL / 
KEPK FK USU-HAM / 2018, Faculty of Medicine, 
University of North Sumatera, Indonesia. The study 
was conducted at the Murni Teguh Memorial Hospital, 
Medan Indonesia. 
 
Subjects 
The patients admitted to the hospital were 
mainly from grade 1 DHF with some grade 2 and a 
few severe DHF. Fifty patients (males 34, females 16) 
admitted to the hospital with fever were recruited and 
diagnosed according to WHO protocol (6) to have 
Grade 1 (n = 41), Grade 2 (n = 6), Grade 3 (n = 2) and 
Grade 4 (n = 1) DHF. The Inclusion criteria: patients 
who met WHO criteria for dengue fever and willing to 
take part in the study and had one or more dengue 
serology positive for either IgM/IgG antibodies or 
NS1antigen, Exclusion criteria: patients with other 
infections and systemic diseases and not willing to 
take part in the study. 
Normal Controls 
Fifteen normal subjects (males n = 14, female 
n = 1) who are normotensive, had not taken any 
medication recently and no history of health issues 
was recruited to serve as normal controls for the DHF 
study. Their mean age was 22.9 ± 1.1 years and 
ranged between 18 years and 33 years old. 
 
Blood Sampling and Laboratory 
 Investigation 
From a clean venepuncture 3 mL EDTA blood 
was used for routine determination of haemoglobin 
(Hb), haematocrit (Hct) and platelets performed in the 
Siemens high volume haematological analyser 
(ADVIA 2120 / 1), and plasma for serological tests for 
IgG / IgM antibodies and NS1 antigen (SD Bioscience, 
Ingbert, Germany). 10 mL of citrated blood was spun 
in the refrigerated centrifuge at 2500g for10 minutes 
and the plasma aliquoted and stored at -80°C. 
Citrated-plasma was used for Elisa analysis of 
prothrombin fragment F1 + 2 (F1+2), Von Willebrand 
Factor (VWF), vascular endothelial growth factor 
(VEGF) (USCN Life Sciences, Wuhan, China) and D-
dimer (Vidas D-dimer Exclusion II, Biomerieux SA 
France). 
 
Statistical Analysis 
The Statistical Package for Social Sciences 
(SPSS 22 IBM Corp) was used to perform statistical 
analysis. The independent t-test for differences 
between groups at different DHF phases was 
performed together with one-way Analysis of Variance 
(ANOVA). A P value of < 0.05 was considered 
statistically significant. 
 
 
Results 
 
Characteristics of patients with dengue 
 haemorrhagic fever 
Petechiae or rash, headaches/bone and pain 
behind eyes are seen in all patients; Epistaxis is seen 
in grades 2 and 3 patients while the grade 4 patient 
was unconscious at admission, had bled into the brain 
at defervescence phase as evident from CT-scan. 
Pleural effusion was only observed in grades 3 and 4 
DHF. The liver enlargement was seen in grades 2, 3 
and 4 and 14.6% (6 / 41) in grade 1. The patients 
were discharged in an afebrile state. The clinical 
characteristics of DHF patients are shown in Table 1.  
Comparison of parameters studied in DHF 
(Grade 1) between cohorts at age seventeen years 
and below and above seventeen years.  
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Table 1: Characteristics of patients with dengue haemorrhagic 
fever  
 Grade 1 Grade 2 Grade 3 Grade 4 
N 41 6 2 1 
Age mean (SD) years 20.6 (11.8) 30.8 (8.7) 38, 43   54 
Sex males/females 28/13 4/2 2/0 1/0 
Petechiae/rash 41 6 2 1 
Pain: 
headache/bones/behind 
eyes 
41 6 2 1 
Nausea 19 6 2 1 
Cough 15 4 1 0 
Bleeding: epitaxis 0 6 2 1* 
Pleural effusion 0 0 2 1 
Liver enlargement 6 6 2 1 
*Bleeding to the brain (CT scan). 
 
There were twenty cohorts (males n = 13, 
females n = 7) at seventeen years and below and 
twenty-one cohorts (males n = 14, females n = 7) 
above 17 years old. Except for the significance in age 
(P ≤ 0.001) and lower mean trend for platelets in the 
above 17 years cohorts which did not reach statistical 
significance (P = 0.05), there were no statistical 
differences in the other parameters studied (not 
shown). They were therefore combined (Grade 1) for 
further statistical analysis. 
Dengue haemorrhagic fever: Comparison of 
parameters studied between Grades 1 and 2 at 
febrile, defervescence and convalescence phases and 
comparison to febrile phase. 
The combined Grade 1 DHF cohorts are 
significantly younger than the Grade 2 cohorts (P = 
0.03). There were no significant differences in the 
other parameters studied between the two groups of 
cohorts at different phases of DHF.  
Platelets had higher mean numbers at a 
convalescent phase in both grades 1 and 2 DHF, but 
they did not reach statistical differences even when 
compared to the febrile phase. Thrombocytopenia 
with elevated F1 + 2, VWF, VEGF and D-dimer was 
observed. Moreover, there was also no significant 
differences in the parameters studied when 
defervescence and convalescence phases were 
compared to febrile phase, except for D-dimer (Grade 
2 DHF) which showed a significant decrease (P = 
0.01) at convalescence compared with febrile phase 
even though it remained elevated (Table 2). 
Analysis of Variance (ANOVA), One-way 
ANOVA analysis for Hb, Hct, platelets, F1 + 2, VWF. 
VEGF in either Grades 1 or 2 between different DHF 
phases showed no statistical differences except for D-
dimer (Grade 2 DHF) showed a significant decrease 
((P = 0.04) at convalescence (not shown). When 
combined {Grades 1 & 2}, ANOVA analysis showed 
no significant differences in the parameters studied. 
Comparison between normal controls against 
combined DHF (Grades 1 & 2) at different phases for 
F1 + 2, VWF, VEGF and D-dimer.  
Grades 1 & 2 DHF were combined to analyse 
against normal controls. There were significant 
differences (P ≤ 0.001) at all phases of DHF for 
elevated F1 + 2, VWF, VEGF and D-dimer levels 
compared with normal controls (Table 3).  
Table 2: Dengue haemorrhage fever: Comparison of 
parameters studied (mean ± SD) between Grades 1 & 2 at 
febrile, defervescence and convalescence phases and 
compared to febrile phase 
 Grade 1 Gr1 – P vs 
Febrile phase 
Grade 2 Gr2- P vs 
Febrile phase 
P 
Gr1 vs Gr2) 
Febrile      
N (male/female) 41 (28/13) 6 (4/2) 
 
   
Age years 20.6 (11.8) 30.8 (8.7)  0.03  
Haemoglobin 
g//L 
13.6 (1.8) 14.3 (2.1)  0.46  
Haematocrit % 40.6 (5.6) 42.8 (6.1  0.45  
Platelets x 10
9
/L 94.8 (70.9 70.5 (60.4)  0.40  
F1 + 2 pg/mL 293.1 (171.5) 296.0 (157.0)  0.97  
VWF ng/mL 109.7 (29.6) 120.0 (29.1)  0.45  
VEGF pg/mL 270.4 (248.6 253.5 (78.1)  0.74  
D-dimer ng/mL 1770.4 (789.3) 1988.6 (472.1)  0.42  
Defervescence      
Haemoglobin 
g//L 
13.6 (1.7) 0.93 14.2 (2.0) 0.91 0.49 
Haematocrit % 41.2 (6.6) 0.64 41.4 (8.3) 0.75 0.96 
Platelets x 10
9
/L 78.4 (51.3) 0.23 66.5 (413) 0.90 0.54 
F1 + 2 pg/mL 350.5 (197.4) 0.93 378.9 (129.7) 0.34 0.66 
VWF ng/mL 114.0 (24.9) 0.48 112.3 (26.1) 0.37 0.89 
VEGF pg/mL 384.7(430.2) 0.27 312.2 (108.5) 0.31 0.65 
D-dimer ng/mL 1829.0 (1499.4) 0.85 1525.2 (617.7) 0.22 0.45 
Convalescence      
Haemoglobin 
g//L 
13.2 (1.7) 0.35 13.6 (1.8) 0.65 0.63 
Haematocrit % 40.1 (5.3) 0.68 40.4 (5.6) 0.50 0.91 
Platelets x 10
9
/L 101.8 (58.8) 0.63 97.0 (55.3) 0.45 0.85 
F1 + 2 pg/mL 313.8 (264,8) 0.67 336.8 (176.2) 0.68 0.79 
VWF ng/mL 113.7 (24.8) 0.51 114.3 (13. 0) 0.68 0.93 
VEGF pg/mL 349.0 (433.8 0.32 467.5 (534.0) 0.37 0.62 
D-dimer ng/mL 1528.1 (1422.8) 0.47 1085.2 (480.7) 0.01 0.16 
 
This suggests that there is endothelial 
activation, plasma leakage triggering the activation of 
coagulation, creating a hypercoagulable and 
fibrinolytic state in DHF.  
Table 3. Comparison between normal controls and combined 
DHF (Grades 1 & 2) at different phases for F1+2, VWF, VEGF 
and D-dimer (mean ± SD) 
 Normal-Control DHF-Febrile 
DHF-
Defervescence 
DHF-
Convalescence 
N 15 47 47 47 
Prothrombin     
Fragment F1+2 
pg/mL 
ND 293.4 (166.1) 354.1 (189.2) 316.8 (263.4)  
P  < 0.001 < 0.001 < 0.001 
VWF ng/mL 1.9 (31.4)* 111.0 (29.6) 113.8 (24.8) 113.8 (23.6) 
P  < 0.001 < 0.001 < 0.001 
VEGF pg/mL 71.7 (27.9) 268.3 (233.4) 340.5 (323.3) 364.2 (442.9 
P  < 0.001 < 0.001 < 0.001 
D-dimer ng/mL < 500 1800.7 (751.9) 1785.6 (1405.1) 1463.8 (1334.8) 
P  < 0.001 < 0.001 < 0.001 
ND = not detectable (F1 + 2 sensitivity < 28.1 pg/mL); * ND (n = 13), VWF sensitivity < 
0.94 ng/mL. 
 
The combined Grades 1 & 2 DHF for VWF, 
VEGF, F1 + 2 and D-dimer at febrile, defervescence 
and convalescence phases with ANOVA analysis and 
normal controls are shown in Figure 1. The results 
from the three severe DHF patients recruited had 
elevated VWF, F1 + 2, VEGF and D-dimer with 
thrombocytopenia similar with grades 1&2 DHF but 
had lower haemoglobin levels. However, the patient 
with severe DHF (grade 4) was unconscious when 
admitted and found to have cerebral bleeding (CT 
scan) at defervescence phase with pleural effusion, 
hypervolemic shock. Thrombocytopenia with platelets 
at 43 x 10
9
/L and elevated D-dimer of 1620 ng/mL at 
admission were given electrolyte and crystalloid 
infusions. The platelet rose to 88 x 10
9
/L, and D-dimer 
level fell to 809 ng/mL at convalescence. His condition 
improved and discharged after two weeks in the 
hospital. The other two patients with grade 3 DHF also 
had pleural effusion and enlarged livers. 
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Figure 1: Mean levels of VWF, VEGF, F1 + 2 and D-dimer levels 
and ANOVA analysis in combined DHF Grades 1 & 2 at febrile, 
defervescence and convalescence phases 
 
Thrombocytopenia was seen in one patient 
(platelets 87x 10
9
/L) at febrile phase and fell to 11 x 
10
9
/L at defervescence phase but rose to 141 x 10
9
/L 
at convalescence. The D-dimer levels of 5296.2 
ng/mL at the febrile phase fell to 620.4 ng/mL at the 
convalescence phase. The other patient had normal 
platelets at admission (173 x 10
9
/L), but severe 
thrombocytopenia was seen in defervescence and 
convalescence phases (4 x 10
9/
L and 37 x 10
9
/l) 
respectively. The D-dimer was 2307.8 ng/mL at 
admission and 2060 ng/ml at convalescence. They 
were given electrolyte infusion and other medications 
and discharged one week later in an afebrile state. 
 
 
Discussion 
 
Dengue fever is the most serious 
consequence of mosquito-borne infection worldwide. 
The pathophysiology of DHF in human is complex as 
its clinical symptoms are mainly due to an immune 
response involving the production of 
cytokine/chemokines as well as endothelial activation, 
T-lymphocytes, monocytes and platelets. Endothelial 
damage may also be caused by the virus itself. 
Thrombocytopenia is responsible for bleeding events 
in DHF [20], [23] but many factors can contribute to 
the onset of thrombocytopenia from a reactive 
immune response against platelets and decreased 
platelet production [11], [24], platelet activation and 
apoptosis [21], Dengue virus could bind directly to 
prothrombin inhibiting the conversion to thrombin [24] 
causing decreased coagulation activation, reduced 
thrombin generation and may be associated with 
bleeding complications in Brazilians with DHF [23] 
The relationship between dengue and activation of 
coagulation is controversial [27]. However, activation 
of coagulation in critical DHF phase was reported in 
Indonesian patients (22), which was contrary to the 
Brazilian study [23]. Bleeding manifestations and 
plasma leakage are complications seen in dengue 
and bleeding manifestation in adults may occur in the 
absence of plasma leakage [28]. 
In our study, petechiae or rash was observed 
in DHF besides the symptoms of pain in the bones, 
behind the eyes and headaches. Bleeding episodes 
like epitaxial were seen in grades 2 and 3 DHF while 
bleeding to the brain occurred in our grade 4 patient. 
Pleural effusion was seen only in severe DHF with 
liver enlargement present in Grades 2, 3 and 4 and 
about 14.6% (6/41) in Grade 1 DHF. 
Thrombocytopenia was observed in all phases of DHF 
even though in the convalescence phase, the mean 
platelet numbers were higher than in febrile and 
defervescence phases they did not reach statistical 
significance between grades 1 & 2 DHF. Normal 
haemoglobin and no haemo-concentration were 
observed, but elevated activation of coagulation (F1 + 
2), VWF, VEGF and D-dimer suggest endothelial 
activation, plasma leakage and activation of 
coagulation in DHF. Activation of coagulation was 
reported earlier in critical DHF [22] in Indonesian 
patients, but contrary to this, Orsi and co-workers [23] 
reported reduced thrombin generation and enhanced 
fibrinolysis contributing to the bleeding episodes in 
Brazilian patients. Reduced thrombin generation could 
result from the dengue virus binding directly to 
prothrombin inhibiting the conversion to thrombin [26]. 
Activation of coagulation and elevated D-dimer levels 
also indicates hypercoagulability and enhanced 
fibrinolysis. Endothelial activation evident by elevated 
VWF and VEGF suggests plasma leakage triggering 
the activation of the coagulation system, creating 
hypercoagulation and enhanced fibrin-lysis state. 
Elevated D-dimer was seen in DHF even at 
convalescence. Normal haemoglobin and no 
haemoconcentration was observed in DHF grades 1 
and 2. No mortality was recorded. Demographic 
differences and genetic make-up may contribute to 
these differences. Identifying the mechanisms 
affecting DHF would improve diagnosis and 
management therapy limiting morbidity and mortality. 
In conclusion, in dengue haemorrhagic fever, 
the vascular endothelium is activated, causing plasma 
leakage triggering the activation of the haemostatic 
system creating a hypercoagulable and enhanced 
fibrinolytic state evident by marked fibrin-lysis. 
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